Overview

* Bruker Q2 2025 revenue falls 0.4% yoy, missing analyst expectations

* Non-GAAP diluted EPS drops 38.5% yoy, missing estimates, per LSEG data

* Co announces cost savings initiative to reduce annual costs by $100-120 mln in FY 2026

Outlook

* Bruker ( BRKR ) expects FY 2025 revenue of $3.43 to $3.50 bln

* Company anticipates FY 2025 non-GAAP EPS of $1.95 to $2.05

* Bruker ( BRKR ) sees organic revenue decline of 2% to 4% in FY 2025

* Company cites US academic market pressure affecting FY 2025 outlook

Result Drivers

* DEMAND PRESSURE - Life-science research instruments demand under pressure, particularly in US academic and biopharma markets, per CEO Frank H. Laukien

* CURRENCY HEADWINDS - Tariffs and currency headwinds impacted results, despite mitigating actions

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $797.40 $811.40

Revenue mln mln (11

Analysts

)

Q2 Miss $0.32 $0.42

Adjusted (12

EPS Analysts

)

Q2 Net $4.20

Income mln

Q2 Gross $357.90

Profit mln

Q2 $346 mln

Operatin

g

Expenses

Q2 $11.90

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Bruker Corp ( BRKR ) is $47.50, about 20% above its August 1 closing price of $37.99

* The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)